ArticleDrug testing and analysis2026
Comparison of Dried Blood Spot Sampling Methods for RNA-Based Biomarker Measurement in Anti-Doping.
Article in Drug testing and analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Dried blood spot (DBS) sampling offers logistical advantages, but it remains unexplored whether analytical results are comparable across DBS sampling methods. This study investigated whether venous or capillary blood spotted on cellulose cards or collected with the Tasso-M20 device provides comparable results for the anti-doping RNA-based biomarkers of erythropoiesis, 5-aminolevulinic acid synthase (ALAS2), and carbonic anhydrase 1 (CA1). In the population of Swiss athletes (n = 12), DBS samples (venous-cellulose and Tasso-M20) were collected in routine anti-doping procedures. In healthy volunteers (n = 12), DBS samples (venous-cellulose, capillary-cellulose and Tasso-M20) were collected at baseline, after 1 week and 10 days post a 3-week recombinant human erythropoietin (rEPO) administration study. ALAS2 and CA1 mRNA were quantified using RT-qPCR, and agreement between matrices was assessed via Passing-Bablok regression. ALAS2 and CA1 expression showed strong linear agreement (r ≥ 0.96) across matrices. Passing-Bablok regression indicated no constant or proportional bias for ALAS2 across all comparisons. For CA1, no bias existed between venous-cellulose and Tasso-M20 in the athlete population, whereas a proportional bias of ~9%-22% was observed when comparing Tasso-M20 DBS with venous- or capillary-cellulose DBS in the rEPO study. No significant differences in relative RNA expression were observed across matrices at any timepoint in the administration study. ALAS2 and CA1 are reliably quantified across venous- and capillary-cellulose-based DBS and Tasso-M20 DBS samples. Strong agreement and minimal bias, with the modest CA1 bias being small relative to expected biological or treatment-induced variability, support their use for longitudinal monitoring, enabling less invasive, flexible, and decentralized sampling in research and anti-doping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.